FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:334-335 February 2, 1995 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Mayer, R. J.

To the Editor: Mayer et al. (Oct. 6 issue)¹ conclude that adults with acute myeloid leukemia (AML) in remission who are 60 years of age or younger benefit from high-dose cytarabine therapy. It should be noted that the population these authors treated was selected to exclude patients with prior hematologic disorders and those who had received cytotoxic chemotherapy or radiation therapy. At the M.D. Anderson Cancer Center, patients with these characteristics made up 23 percent (107 of 472) of the adults 60 years of age or younger who entered complete remission after receiving chemotherapy for previously untreated AML between 1980 . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.